E-ISSN 2602-3164
EJMI. 2022; 6(4): 450-455 | DOI: 10.14744/ejmi.2022.15573

Mortality Rate and Related Factors in Patients with Active Oncological Malignancies Hospitalized for Covid-19

Cengiz Yilmaz1, Ismail Demir2
1Department of Medical Oncology, University of Health Sciences, Bozyaka Training and Research Hospital, Izmir, Türkiye, 2Department of Internal Medicine, University of Health Sciences, Bozyaka Training and Research Hospital, Izmir, Türkiye

Objectives: To investigate the mortality rate and mortality-related factors for patients with oncological malignancies (cancer patients) hospitalized for Covid-19 infection. Methods: Demographic characteristics, hematological and biochemical parameters, lung CT Severity Scores (CT-SS), and Charlson Comorbidity Indices (CCI) of living and dead oncology patients were compared. Statistical analyses of possible factors that may impact mortality were performed. Results: The overall mortality rate of 2650 patients hospitalized for Covid-19 was 21%. Among these, 410 patients had active oncological malignancy. The mortality rate of the oncology patients was significantly higher than those without any malignancy (54% vs. 7.2%, p<0.0001). Logistic regression analyses revealed that CT-SS, neutrophil count, hemoglobin, and CCI had meaningful independent effects on mortality in patients with oncological malignancies. The mean CTSS was significantly higher in the ex-group than the alive group (17.6±5.5 vs. 15.3±4.8, p<0.0001). On the other hand, the mean neutrophil count (2100±830 vs. 4350±660 p <0.0001) and hemoglobin level (8.4±3.2 vs. 10.7±2.8, p<0.0001) were statistically lower. Conclusion: Covid-19 (+) oncology patients suffering from profound anemia, neutropenia, and substantial lung involvement have markedly high mortality and should be treated intensely and meticulously. Keywords: Covid-19, cancer patients, mortality, oncological malignancy


Cite This Article

Yilmaz C, Demir I. Mortality Rate and Related Factors in Patients with Active Oncological Malignancies Hospitalized for Covid-19. EJMI. 2022; 6(4): 450-455

Corresponding Author: Cengiz Yilmaz

Full Text PDF PDF Download
EJMI & EJMI